The management of orthostatic hypotension in Parkinson's disease

Frontiers in Neurology

Volumn 4 JUN, Issue , 2013, Pages

  Sánchez Ferro, varo ^a,b,c,d   Benito León, Julián ^a,b,c   Gómez Esteban, Juan Carlos ^e  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

continuous dopaminergic stimulation; Dopamine agonists; L DOPA; Orthostatic hypotension; Parkinson's disease; Treatment

Indexed keywords

AMANTADINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CAFFEINE; CAFFEINE PLUS ERGOTAMINE TARTRATE; CLONIDINE; DESMOPRESSIN; DOMPERIDONE; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; EPHEDRINE; ERYTHROPOIETIN; ETILEFRINE; FLUDROCORTISONE; FLUOXETINE; GLYCERYL TRINITRATE; LEVODOPA; MIDODRINE; MONOAMINE OXIDASE INHIBITOR; OCTREOTIDE; PYRIDOSTIGMINE; RASAGILINE; ROPINIROLE; SELEGILINE; THREO 3,4 DIHYDROXYPHENYLSERINE; YOHIMBINE;

ARTICLE; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE MEASUREMENT; BRAIN DEPTH STIMULATION; CLINICAL FEATURE; COLIC; COMPRESSION STOCKING; CONFUSION; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DIARRHEA; DISEASE CONTROL; DISEASE DURATION; DIZZINESS; DOPAMINERGIC TRANSMISSION; DRUG ANTAGONISM; DRUG INDUCED HEADACHE; DRUG MEGADOSE; EDEMA; FATIGUE; HUMAN; HYPERSALIVATION; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; INJECTION SITE REACTION; NAUSEA; NERVOUSNESS; NEUROLEPTIC MALIGNANT SYNDROME; NEUROPROTECTION; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PARKINSON DISEASE; PATIENT CARE; POLYURIA; POSTPRANDIAL HYPOTENSION; PRURITUS; REFLEX; SIDE EFFECT; TREATMENT OUTCOME; TREMOR; VISUAL DISORDER;

EID: 84883533627     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2013.00064     Document Type: Article

References (149)

1. Abassi, Z. A., Binah, O., and Youdim, M. B. (2004). Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline. Br. J. Pharmacol. 143, 371-378. doi:10.1038/sj.bjp.0705962
2. Allcock, L. M., Kenny, R. A., and Burn, D. J. (2006). Clinical phenotype of subjects with Parkinson's disease and orthostatic hypotension: autonomic symptom and demographic comparison. Mov. Disord. 21, 1851-1855. doi:10.1002/mds.20996
3. Allcock, L. M., Ullyart, K., Kenny, R. A., and Burn, D. J. (2004). Frequency of orthostatic hypotension in a community based cohort of patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatr. 75, 1470-1471. doi:10.1136/jnnp.2003.029413
4. Arbogast, S. D., Alshekhlee, A., Hussain, Z., McNeeley, K., and Chelimsky, T. C. (2009). Hypotension unawareness in profound orthostatic hypotension. Am. J. Med. 122, 574-580. doi:10.1016/j.amjmed.2008.10.040
5. Awerbuch, G. I., and Sandyk, R. (1992). Autonomic functions in the early stages of Parkinson's disease. Int. J. Neurosci. 64, 7-14. doi:10.3109/00207459209000530
6. Barbeau, A. (1969). L-dopa therapy in Parkinson's disease: a critical review of nine years' experience. Can. Med. Assoc. J. 101, 59-68.
7. Barbeau, A., Gillo-Joffroy, L., Boucher, R., Nowaczynski, W., and Genest, J. (1969). Renin-aldosterone system in Parkinson's disease. Science 165, 291-292. doi:10.1126/science.165.3890.291
8. Benedetti, F., Colloca, L., Lanotte, M., Bergamasco, B., Torre, E., and Lopiano, L. (2004). Autonomic and emotional responses to open and hidden stimulations of the human subthalamic region. Brain Res. Bull. 63, 203-211. doi:10.1016/j.brainresbull.2004.01.010
9. Berganzo, K., Diez-Arrola, B., Tijero, B., Somme, J., Lezcano, E., Llorens, V., et al. (2013). Nocturnal hypertension and dysautonomia in patients with Parkinson's disease: are they related? J. Neurol. doi:10.1007/s00415-013-6859-5. [Epub ahead of print].
10. Bhattacharya, K. F., Nouri, S., Olanow, C. W., Yahr, M. D., and Kaufmann, H. (2003). Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension. Parkinsonism Relat. Disord. 9, 221-224. doi:10.1016/S1353-8020(02)00053-6
11. Boehringer Ingelheim Pharmaceuticals. (2003). "A 12-week study of pramipexole ER in patients with Parkinson's disease, followed by a 52-week long-term treatment period," in ClinicalTrials.gov (Bethesda, MD: US National Library of Medicine). Available at: http://www.clinicaltrials.gov/ct2/show/results/NCT00560508 [accessed February 22, 2013].
12. Bordet, R., Benhadjali, J., Destee, A., Belabbas, A., and Libersa, C. (1995). Octreotide effects on orthostatic hypotension in patients with multiple system atrophy: a controlled study of acute administration. Clin. Neuropharmacol. 18, 83-89. doi:10.1097/00002826-199502000-00012
13. Borgohain, R., Kandadai, R. M., Jabeen, A., and Kannikannan, M. A. (2012). Nonmotor outcomes in Parkinson's disease: is deep brain stimulation better than dopamine replacement therapy? Ther. Adv. Neurol. Disord. 5, 23-41. doi:10.1177/1756285611423412
14. Bouhaddi, M., Vuillier, F., Fortrat, J. O., Cappelle, S., Henriet, M. T., Rumbach, L., et al. (2004). Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson's disease: involvement of L-dopa therapy. Auton. Neurosci. 116, 30-38. doi:10.1016/j.autneu.2004.06.009
15. Bouvette, C. M., McPhee, B. R., Opfer-Gehrking, T. L., and Low, P. A. (1996). Role of physical countermaneuvers in the management of orthostatic hypotension: efficacy and biofeedback augmentation. Mayo Clin. Proc. 71, 847-853. doi:10.4065/71.9.847
16. Brooks, D. J., Redmond, S., Mathias, C. J., Bannister, R., and Symon, L. (1989). The effect of orthostatic hypotension on cerebral blood flow and middle cerebral artery velocity in autonomic failure, with observations on the action of ephedrine. J. Neurol. Neurosurg. Psychiatr. 52, 962-966. doi:10.1136/jnnp.52.8.962
17. Brunt, E. R., Brooks, D. J., Korczyn, A. D., Montastruc, J. L., and Stocchi, F. (2002). A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. J. Neural Transm. 109, 489-502. doi:10.1007/s007020200040
18. Calne, D. B., Brennan, J., Spiers, A. S., and Stern, G. M. (1970). Hypotension caused by L-dopa. Br. Med. J. 1, 474-475. doi:10.1136/bmj.1.5694.474
19. Camerlingo, M., Ferraro, B., Gazzaniga, G. C., Casto, L., Cesana, B. M., and Mamoli, A. (1990). Cardiovascular reflexes in Parkinson's disease: long-term effects of levodopa treatment on de novo patients. Acta Neurol. Scand. 81, 346-348. doi:10.1111/j.1600-0404.1990.tb01568.x
20. Chaudhuri, K. R., Ellis, C., Love-Jones, S., Thomaides, T., Clift, S., Mathias, C. J., et al. (1997). Postprandial hypotension and parkinsonian state in Parkinson's disease. Mov. Disord. 12, 877-884. doi:10.1002/mds.870120608
21. Chaudhuri, K. R., Thomaides, T., Watson, L., and Mathias, C. J. (1995). Octreotide reduces alcohol-induced hypotension and orthostatic symptoms in primary autonomic failure. QJM 88, 719-725.
22. Chitsaz, A., Saadatnia, M., Etemadifar, M., and Tajmirriahi, M. (2007). Orthostatic hypotension in Iranian patients with Parkinson's disease. Neurosciences (Riyadh) 12, 133-135.
23. Churchyard, A., Mathias, C. J., Boonkongchuen, P., and Lees, A. J. (1997). Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J. Neurol. Neurosurg. Psychiatr. 63, 228-234. doi:10.1136/jnnp.63.2.228
24. Churchyard, A., Mathias, C. J., and Lees, A. J. (1999). Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal. Mov. Disord. 14, 246-251. doi:10.1002/1531-8257(199903)14:2 < 246::AID-MDS1008 > 3.0.CO;2-P
25. Corsini, G. U., Del Zompo, M., Gessa, G. L., and Mangoni, A. (1979). Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease. Lancet 1, 954-956. doi:10.1016/S0140-6736(79)91725-2
26. Deguchi, K., Ikeda, K., Sasaki, I., Shimamura, M., Urai, Y., Tsukaguchi, M., et al. (2007). Effects of daily water drinking on orthostatic and postprandial hypotension in patients with multiple system atrophy. J. Neurol. 254, 735-740. doi:10.1007/s00415-006-0425-3
27. Denq, J. C., Opfer-Gehrking, T. L., Giuliani, M., Felten, J., Convertino, V. A., and Low, P. A. (1997). Efficacy of compression of different capacitance beds in the amelioration of orthostatic hypotension. Clin. Auton. Res. 7, 321-326. doi:10.1007/BF02267725
28. Dewey, R. B. Jr., Rao, S. D., Holmburg, S. L., and Victor, R. G. (1998). Ergotamine/caffeine treatment of orthostatic hypotension in parkinsonism with autonomic failure. Eur. J. Neurol. 5, 593-599. doi:10.1046/j.1468-1331.1998.560593.x
29. Diedrich, A., and Biaggioni, I. (2004). Segmental orthostatic fluid shifts. Clin. Auton. Res. 14, 146-147. doi:10.1007/s10286-004-0188-9
30. Duby, S. E., Cotzias, G. C., Papavasiliou, P. S., and Lawrence, W. H. (1972). Injected apomorphine and orally administered levodopa in parkinsonism. Arch. Neurol. 27, 474-480. doi:10.1001/archneur.1972.00490180010004
31. Erola, T., Haapaniemi, T., Heikkinen, E., Huikuri, H., and Myllya, V. (2006). Subthalamic nucleus deep brain stimulation does not alter long-term heart rate variability in Parkinson's disease. Clin. Auton. Res. 16, 286-288. doi:10.1007/s10286-006-0354-3
32. Etminan, M., Gill, S., and Samii, A. (2003). Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis. Drug Saf. 26, 439-444. doi:10.2165/00002018-200326060-00005
33. Fedorowski, A., Stavenow, L., Hedblad, B., Berglund, G., Nilsson, P. M., and Melander, O. (2010). Orthostatic hypotension predicts all-cause mortality and coronary events in middle-aged individuals (The Malmo Preventive Project). Eur. Heart J. 31, 85-91. doi:10.1093/eurheartj/ehp329
34. Fernandez, H. H., Vanagunas, A., Odin, P., Espay, A. J., Hauser, R. A., Standaert, D. G., et al. (2013). Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: Interim results. Parkinsonism Relat. Disord. 19, 339-345. doi:10.1016/j.parkreldis.2012.11.020
35. Figueroa, J. J., Basford, J. R., and Low, P. A. (2010). Preventing and treating orthostatic hypotension: as easy as A, B, C. Cleve. Clin. J. Med. 77, 298-306. doi:10.3949/ccjm.77a.09118
36. Freeman, R. (2008). Clinical practice. Neurogenic orthostatic hypotension. N. Engl. J. Med. 358, 615-624. doi:10.1056/NEJMcp074189
37. Freeman, R., Wieling, W., Axelrod, F. B., Benditt, D. G., Benarroch, E., Biaggioni, I., et al. (2011). Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin. Auton. Res. 21, 69-72. doi:10.1007/s10286-011-0119-5
38. Giladi, N., Boroojerdi, B., Korczyn, A. D., Burn, D. J., Clarke, C. E., and Schapira, A. H. (2007). Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov. Disord. 22, 2398-2404. doi:10.1002/mds.21741
39. GlaxoSmithKline. (2003a). "Clinical evaluation of ropirinole prolonged release/extended release (PR/XR) tablet for adjunctive therapy to L-dopa in subjects with advanced Parkinson's disease," in ClinicalTrials.gov (Bethesda, MD: US National Library of Medicine). Available at: http://www.clinicaltrials.gov/ct2/show/results/NCT00823836 [accessed February 22, 2013].
40. GlaxoSmithKline. (2003b). "REQUIP (ropinirole hydrochloride) IR long-term phase 4 study," in ClinicalTrials.gov (Bethesda, MD: US National Library of Medicine). Available at: http://www.clinicaltrials.gov/ct2/show/results/NCT00485069 [accessed February 22, 2013].
41. Goetz, C. G., Lutge, W., and Tanner, C. M. (1986). Autonomic dysfunction in Parkinson's disease. Neurology 36, 73-75. doi:10.1212/WNL.36.1.73
42. Goldberg, L. I., and Whitsett, T. L. (1971). Cardiovascular effects of levodopa. JAMA 218, 1921-1923. doi:10.1001/jama.1971.03190260037010
43. Gupta, D., and Nair, M. D. (2008). Neurogenic orthostatic hypotension: chasing "the fall." Postgrad. Med. J. 84, 6-14. doi:10.1136/pgmj.2007.062075
44. Guttman, M. (1997). Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology 49, 1060-1065. doi:10.1212/WNL.49.4.1060
45. Haapaniemi, T. H., Kallio, M. A., Korpelainen, J. T., Suominen, K., Tolonen, U., Sotaniemi, K. A., et al. (2000). Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson's disease. J. Neurol. 247, 868-874. doi:10.1007/s004150070075
46. Hoehn, M. M. (1975). Levodopa-induced postural hypotension. Treatment with fludrocortisone. Arch. Neurol. 32, 50-51. doi:10.1001/archneur.1975.00490430072013
47. Hoeldtke, R. D., Horvath, G. G., Bryner, K. D., and Hobbs, G. R. (1998). Treatment of orthostatic hypotension with midodrine and octreotide. J. Clin. Endocrinol. Metab. 83, 339-343. doi:10.1210/jc.83.2.339
48. Hoeldtke, R. D., and Israel, B. C. (1989). Treatment of orthostatic hypotension with octreotide. J. Clin. Endocrinol. Metab. 68, 1051-1059. doi:10.1210/jcem-68-6-1051
49. Hoeldtke, R. D., and Streeten, D. H. (1993). Treatment of orthostatic hypotension with erythropoietin. N. Engl. J. Med. 329, 611-615. doi:10.1056/NEJM199308263290904
50. Hollenberg, N. K. (2006). The influence of dietary sodium on blood pressure. J. Am. Coll. Nutr. 25(Suppl. 3), 240S-246S.
51. Holmberg, B., Corneliusson, O., and Elam, M. (2005). Bilateral stimulation of nucleus subthalamicus in advanced Parkinson's disease: no effects on, and of, autonomic dysfunction. Mov. Disord. 20, 976-981. doi:10.1002/mds.20492
52. Hubble, J. P., Koller, W. C., Cutler, N. R., Sramek, J. J., Friedman, J., Goetz, C., et al. (1995). Pramipexole in patients with early Parkinson's disease. Clin. Neuropharmacol. 18, 338-347. doi:10.1097/00002826-199508000-00006
53. Hughes, A. J., Daniel, S. E., Kilford, L., and Lees, A. J. (1992). Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatr. 55, 181-184. doi:10.1136/jnnp.55.3.181
54. Ito, D., Amano, T., Sato, H., and Fukuuchi, Y. (2001). Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease. J. Neurol. 248, 533-534. doi:10.1007/s004150170168
55. Ives, N. J., Stowe, R. L., Marro, J., Counsell, C., Macleod, A., Clarke, C. E., et al. (2004). Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ 329, 593. doi:10.1136/bmj.38184.606169.AE
56. Jankovic, J., Gilden, J. L., Hiner, B. C., Kaufmann, H., Brown, D. C., Coghlan, C. H., et al. (1993). Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am. J. Med. 95, 38-48. doi:10.1016/0002-9343(93)90230-M
57. Jordan, J., Shannon, J. R., Grogan, E., Biaggioni, I., and Robertson, D. (1999a). A potent pressor response elicited by drinking water. Lancet 353, 723. doi:10.1016/S0140-6736(99)99015-3
58. Jordan, J., Shannon, J. R., Pohar, B., Paranjape, S. Y., Robertson, D., Robertson, R. M., et al. (1999b). Contrasting effects of vasodilators on blood pressure and sodium balance in the hypertension of autonomic failure. J. Am. Soc. Nephrol. 10, 35-42.
59. Kaufmann, H. (1996). Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Clin. Auton. Res. 6, 125-126. doi:10.1007/BF02291236
60. Kaufmann, H. (2008). L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience. Clin. Auton. Res. 18(Suppl. 1), 19-24. doi:10.1007/s10286-007-1002-2
61. Kaufmann, H., and Goldstein, D. S. (2007). Autonomic dysfunction in Parkinson's disease. Handb. Clin. Neurol. 83, 343-363. doi:10.1016/S0072-9752(07)83014-4
62. Keenan, R. E. (1970). The Eaton Collaborative Study of levodopa therapy in parkinsonism: a summary. Neurology 20, 46-59. doi:10.1212/WNL.20.12_Part_2.46
63. Koller, W., Lees, A., Doder, M., and Hely, M. (2001). Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations. Mov. Disord. 16, 858-866. doi:10.1002/mds.1175
64. Korchounov, A., Kessler, K. R., and Schipper, H. I. (2004). Differential effects of various treatment combinations on cardiovascular dysfunction in patients with Parkinson's disease. Acta Neurol. Scand. 109, 45-51. doi:10.1034/j.1600-0404.2003.00172.x
65. Korczyn, A. D., Brunt, E. R., Larsen, J. P., Nagy, Z., Poewe, W. H., and Ruggieri, S. (1999). A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group. Neurology 53, 364-370. doi:10.1212/WNL.53.2.364
66. Kujawa, K., Leurgans, S., Raman, R., Blasucci, L., and Goetz, C. G. (2000). Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch. Neurol. 57, 1461-1463. doi:10.1001/archneur.57.10.1461
67. Kulisevsky, J., and Pagonabarraga, J. (2010). Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials. Drug Saf. 33, 147-161. doi:10.2165/11319860-000000000-00000
68. Lahrmann, H., Cortelli, P., Hilz, M., Mathias, C. J., Struhal, W., and Tassinari, M. (2006). EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur. J. Neurol. 13, 930-936. doi:10.1111/j.1468-1331.2006.01512.x
69. Lang, A. (2001). Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease: the Role of Domperidone Therapy (letter). Arch. Neurol. 58, 835. doi:10.1001/archneur.58.5.835
70. Larina, I. M., Noskov, V. B., Nichiporuk, I. A., Pastushkova, L., and Vasil'eva, G. (2009). Desmopressin effect on water-salt homeostasis and orthostatic tolerance during head-down tilting. Aviakosm. Ekolog. Med. 43, 68-72.
71. Lees, A. J. (1995). Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. BMJ 311, 1602-1607. doi:10.1136/bmj.311.7020.1602
72. Leibowitz, M., and Lieberman, A. (1975). Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone on the cardiovascular system of patients with Parkinson's disease. Neurology 25, 917-921. doi:10.1212/WNL.25.10.917
73. Lieberman, A., Olanow, C. W., Sethi, K., Swanson, P., Waters, C. H., Fahn, S., et al. (1998). A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology 51, 1057-1062. doi:10.1212/WNL.51.4.1057
74. Lipp, A., Tank, J., Trottenberg, T., Kupsch, A., Arnold, G., and Jordan, J. (2005). Sympathetic activation due to deep brain stimulation in the region of the STN. Neurology 65, 774-775. doi:10.1212/01.wnl.0000174436.36399.ca
75. Lipsitz, L. A., Jansen, R. W., Connelly, C. M., Kelley-Gagnon, M. M., and Parker, A. J. (1994). Haemodynamic and neurohumoral effects of caffeine in elderly patients with symptomatic postprandial hypotension: a double-blind, randomized, placebo-controlled study. Clin. Sci. 87, 259-267.
76. Low, P. A., Gilden, J. L., Freeman, R., Sheng, K. N., and McElligott, M. A. (1997). Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA 277, 1046-1051. doi:10.1001/jama.1997.03540370036033
77. Low, P. A., and Singer, W. (2008). Management of neurogenic orthostatic hypotension: an update. Lancet Neurol. 7, 451-458. doi:10.1016/S1474-4422(08)70088-7
78. Ludwig, J., Remien, P., Guballa, C., Binder, A., Binder, S., Schattschneider, J., et al. (2007). Effects of subthalamic nucleus stimulation and levodopa on the autonomic nervous system in Parkinson's disease. J. Neurol. Neurosurg. Psychiatr. 78, 742-745. doi:10.1136/jnnp.2006.103739
79. Lyytinen, J., Sovijarvi, A., Kaakkola, S., Gordin, A., and Teravainen, H. (2001). The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson's disease. Clin. Neuropharmacol. 24, 50-57. doi:10.1097/00002826-200101000-00009
80. Martin, W. E., Loewenson, R. B., Resch, J. A., and Baker, A. B. (1974). A controlled study comparing trihexyphenidyl hydrochloride plus levodopa with placebo plus levodopa in patients with Parkinson's disease. Neurology 24, 912-919. doi:10.1212/WNL.24.10.912
81. Mathias, C. J. (2008). L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience. Clin. Auton. Res. 18(Suppl. 1), 25-29. doi:10.1007/s10286-007-1005-z
82. Mathias, C. J., Fosbraey, P., da Costa, D. F., Thornley, A., and Bannister, R. (1986). The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure. Br. Med. J. (Clin. Res. Ed.) 293, 353-354. doi:10.1136/bmj.293.6543.353
83. Mathias, C. J., and Young, T. M. (2004). Water drinking in the management of orthostatic intolerance due to orthostatic hypotension, vasovagal syncope and the postural tachycardia syndrome. Eur. J. Neurol. 11, 613-619. doi:10.1111/j.1468-1331.2004.00840.x
84. Maule, S., Milazzo, V., Maule, M. M., Di Stefano, C., Milan, A., and Veglio, F. (2012). Mortality and prognosis in patients with neurogenic orthostatic hypotension. Funct. Neurol. 27, 101-106.
85. McDowell, F. H., and Lee, J. E. (1970). Levodopa, Parkinson's disease, and hypotension. Ann. Intern. Med. 72, 751-752. doi:10.7326/0003-4819-72-5-751
86. Metzler, M., Duerr, S., Granata, R., Krismer, F., Robertson, D., and Wenning, G. K. (2012). Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management. J. Neurol. doi:10.1007/s00415-012-6736-7. [Epub ahead of print].
87. Miller, E., Wiener, L., and Bloomfield, D. (1973). Etilefrine in the treatment of levodopa-induced orthostatic hypotension. Arch. Neurol. 29, 99-103. doi:10.1001/archneur.1973.00490260043008
88. Montastruc, J. L., Chamontin, B., Senard, J. M., and Rascol, A. (1985). Domperidone in the management of orthostatic hypotension. Clin. Neuropharmacol. 8, 191-192. doi:10.1097/00002826-198506000-00010
89. Montastruc, J. L., Pelat, M., Verwaerde, P., Brefel-Courbon, C., Tran, M. A., Blin, O., et al. (1998). Fluoxetine in orthostatic hypotension of Parkinson's disease: a clinical and experimental pilot study. Fundam. Clin. Pharmacol. 12, 398-402. doi:10.1111/j.1472-8206.1998.tb00963.x
90. Mostile, G., and Jankovic, J. (2009). Treatment of dysautonomia associated with Parkinson's disease. Parkinsonism Relat. Disord. 15(Suppl. 3), S224-S232. doi:10.1016/S1353-8020(09)70820-X
91. Muller, B., Larsen, J. P., Wentzel-Larsen, T., Skeie, G. O., and Tysnes, O. B. (2011). Autonomic and sensory symptoms and signs in incident, untreated Parkinson's disease: frequent but mild. Mov. Disord. 26, 65-72. doi:10.1002/mds.23387
92. Narkiewicz, K., Cooley, R. L., and Somers, V. K. (2000). Alcohol potentiates orthostatic hypotension: implications for alcohol-related syncope. Circulation 101, 398-402. doi:10.1161/01.CIR.101.4.398
93. Novartis Pharmaceuticals. (2003a). "Efficacy and safety of carbidopa/levodopa/entacapone in patients with Parkinson's disease requiring initiation of levodopa therapy (STRIDE-PD)," in ClinicalTrials.gov (Bethesda, MD: US National Library of Medicine). Available at: http://www.clinicaltrials.gov/ct2/show/results/NCT00099268 [accessed February 22, 2013].
94. Novartis Pharmaceuticals. (2003b). "Long-term safety of rivastigmine capsule and patch in patients with mild to moderately-severe dementia associated with Parkinson's disease (PDD)," in ClinicalTrials.gov (Bethesda, MD: US National Library of Medicine). Available at: http://www.clinicaltrials.gov/ct2/show/results/NCT00623103 [accessed February 22, 2013].
95. Nozaki, S., Kang, J., Miyai, I., and Matsumura, T. (1993). Postprandial hypotension in Parkinson's disease - the incidence and risk factor. Rinsho Shinkeigaku 33, 1135-1139.
96. O'Donnell, M. J., Yusuf, S., Mente, A., Gao, P., Mann, J. F., Teo, K., et al. (2011). Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA 306, 2229-2238. doi:10.1001/jama.2011.1729
97. Olanow, C. W., Kieburtz, K., Stern, M., Watts, R., Langston, J. W., Guarnieri, M., et al. (2004). Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch. Neurol. 61, 1563-1568. doi:10.1001/archneur.61.10.1563
98. Olanow, C. W., Rascol, O., Hauser, R., Feigin, P. D., Jankovic, J., Lang, A., et al. (2009). A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N. Engl. J. Med. 361, 1268-1278. doi:10.1056/NEJMoa0809335
99. Omboni, S., Smit, A. A., van Lieshout, J. J., Settels, J. J., Langewouters, G. J., and Wieling, W. (2001). Mechanisms underlying the impairment in orthostatic tolerance after nocturnal recumbency in patients with autonomic failure. Clin. Sci. 101, 609-618. doi:10.1042/CS20010071
100. Ondo, W. G., Hunter, C., Ferrara, J. M., and Mostile, G. (2012). Apomorphine injections: predictors of initial common adverse events and long term tolerability. Parkinsonism Relat. Disord. 18, 619-622. doi:10.1016/j.parkreldis.2012.01.001
101. Onrot, J., Goldberg, M. R., Biaggioni, I., Wiley, R. G., Hollister, A. S., and Robertson, D. (1987). Oral yohimbine in human autonomic failure. Neurology 37, 215-220. doi:10.1212/WNL.37.2.215
102. Pahwa, R., Koller, W. C., Trosch, R. M., and Sherry, J. H. (2007a). Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. J. Neurol. Sci. 258, 137-143. doi:10.1016/j.jns.2007.03.013
103. Pahwa, R., Stacy, M. A., Factor, S. A., Lyons, K. E., Stocchi, F., Hersh, B. P., et al. (2007b). Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 68, 1108-1115. doi:10.1212/01.wnl.0000258660.74391.c1
104. Parkinson, J. (2002). An essay on the shaking palsy (1817). J. Neuropsychiatry Clin. Neurosci. 14, 223-236. doi:10.1176/appi.neuropsych.14.2.223 discussion 2.
105. Parkinson Study Group. (2004). A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 61, 561-566. doi:10.1001/archneur.61.4.561
106. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch. Neurol. 62, 241-248. doi:10.1001/archneur.62.2.241
107. Pathak, A., and Senard, J. M. (2004). Pharmacology of orthostatic hypotension in Parkinson's disease: from pathophysiology to management. Expert Rev. Cardiovasc. Ther. 2, 393-403. doi:10.1586/14779072.2.3.393
108. Perera, R., Isola, L., and Kaufmann, H. (1995). Effect of recombinant erythropoietin on anemia and orthostatic hypotension in primary autonomic failure. Clin. Auton. Res. 5, 211-213. doi:10.1007/BF01824009
109. Perez-Lloret, S., Rey, M. V., Fabre, N., Ory, F., Spampinato, U., Senard, J. M., et al. (2012). Factors related to orthostatic hypotension in Parkinson's disease. Parkinsonism Relat. Disord. 18, 501-505. doi:10.1016/j.parkreldis.2012.01.012
110. Perez-Lloret, S., Toblli, J. E., Cardinali, D. P., Malateste, J. C., and Milei, J. (2008). Nocturnal hypertension defined by fixed cut-off limits is a better predictor of left ventricular hypertrophy than non-dipping. Int. J. Cardiol. 127, 387-389. doi:10.1016/j.ijcard.2007.04.027
111. Pinter, M. M., Pogarell, O., and Oertel, W. H. (1999). Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study. J. Neurol. Neurosurg. Psychiatr. 66, 436-441. doi:10.1136/jnnp.66.4.436
112. Poewe, W., Rascol, O., Barone, P., Hauser, R. A., Mizuno, Y., Haaksma, M., et al. (2011). Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial. Neurology 77, 759-766. doi:10.1212/WNL.0b013e31822affb0
113. Poewe, W. H., Rascol, O., Quinn, N., Tolosa, E., Oertel, W. H., Martignoni, E., et al. (2007). Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 6, 513-520. doi:10.1016/S1474-4422(07)70108-4
114. Pursiainen, V., Lyytinen, J., and Pekkonen, E. (2012). Effect of duodenal levodopa infusion on blood pressure and sweating. Acta Neurol. Scand. 126, e20-e24. doi:10.1111/j.1600-0404.2012.01648.x
115. Rappelli, A., Glorioso, N., Tedde, R., Dessi'-Fulgheri, P., and Monaco, F. (1978). Effects of levodopa alone and in combination with dopa-decarboxylase inhibitors on plasma renin activity in patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatr. 41, 915-918. doi:10.1136/jnnp.41.10.915
116. Rascol, O., Brooks, D. J., Melamed, E., Oertel, W., Poewe, W., Stocchi, F., et al. (2005). Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365, 947-954. doi:10.1016/S0140-6736(05)71083-7
117. Rascol, O., Fitzer-Attas, C. J., Hauser, R., Jankovic, J., Lang, A., Langston, J. W., et al. (2011). A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 10, 415-423. doi:10.1016/S1474-4422(11)70073-4
118. Rose, L. M., Ohlinger, M. J., and Mauro, V. F. (2000). A hypertensive reaction induced by concurrent use of selegiline and dopamine. Ann. Pharmacother. 34, 1020-1024. doi:10.1345/aph.19221
119. Sachs, C., Berglund, B., and Kaijser, L. (1985). Autonomic cardiovascular responses in parkinsonism: effect of levodopa with dopa-decarboxylase inhibition. Acta Neurol. Scand. 71, 37-42. doi:10.1111/j.1600-0404.1985.tb03164.x
120. Schapira, A. H., Barone, P., Hauser, R. A., Mizuno, Y., Rascol, O., Busse, M., et al. (2011). Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology 77, 767-774. doi:10.1212/WNL.0b013e31822affdb
121. Schoffer, K. L., Henderson, R. D., O'Maley, K., and O'Sullivan, J. D. (2007). Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov. Disord. 22, 1543-1549. doi:10.1002/mds.21428
122. Senard, J. M., Brefel, C., Carel, C., Tran, M. A., and Montastruc, J. L. (1999). Water drinking and the heart. Lancet 353, 1971-1972. doi:10.1016/S0140-6736(05)77183-X
123. Senard, J. M., Brefel-Courbon, C., Rascol, O., and Montastruc, J. L. (2001). Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging 18, 495-505. doi:10.2165/00002512-200118070-00003
124. Senard, J. M., Rai, S., Lapeyre-Mestre, M., Brefel, C., Rascol, O., Rascol, A., et al. (1997). Prevalence of orthostatic hypotension in Parkinson's disease. J. Neurol. Neurosurg. Psychiatr. 63, 584-589. doi:10.1136/jnnp.63.5.584
125. Seppi, K., Weintraub, D., Coelho, M., Perez-Lloret, S., Fox, S. H., Katzenschlager, R., et al. (2011). The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov. Disord. 26(Suppl. 3), S42-80. doi:10.1002/mds.23884
126. Shannon, J. R., Diedrich, A., Biaggioni, I., Tank, J., Robertson, R. M., Robertson, D., et al. (2002). Water drinking as a treatment for orthostatic syndromes. Am. J. Med. 112, 355-360. doi:10.1016/S0002-9343(02)01025-2
127. Shibao, C., Gamboa, A., Abraham, R., Raj, S. R., Diedrich, A., Black, B., et al. (2006). Clonidine for the treatment of supine hypertension and pressure natriuresis in autonomic failure. Hypertension 47, 522-526. doi:10.1161/01.HYP.0000199982.71858.11
128. Shibao, C., Okamoto, L. E., Gamboa, A., Yu, C., Diedrich, A., Raj, S. R., et al. (2010). Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. Hypertension 56, 847-851. doi:10.1161/HYPERTENSIONAHA.110.154898
129. Singer, W., Sandroni, P., Opfer-Gehrking, T. L., Suarez, G. A., Klein, C. M., Hines, S., et al. (2006). Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch. Neurol. 63, 513-518. doi:10.1001/archneur.63.4.noc50340
130. Stemper, B., Beric, A., Welsch, G., Haendl, T., Sterio, D., and Hilz, M. J. (2006). Deep brain stimulation improves orthostatic regulation of patients with Parkinson disease. Neurology 67, 1781-1785. doi:10.1212/01.wnl.0000244416.30605.f1
131. Stocchi, F., Hersh, B. P., Scott, B. L., Nausieda, P. A., and Giorgi, L. (2008). Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. Curr. Med. Res. Opin. 24, 2883-2895. doi:10.1185/03007990802387130
132. Stowe, R., Ives, N., Clarke, C. E., van Hilten, J., Ferreira, J., Hawker, R. J., et al. (2008). Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst. Rev. 2008:CD006564. doi:10.1002/14651858.CD006564.pub2
133. Tanaka, H., Yamaguchi, H., and Tamai, H. (1997). Treatment of orthostatic intolerance with inflatable abdominal band. Lancet 349, 175. doi:10.1016/S0140-6736(97)24003-1
134. Ten Harkel, A. D., Van Lieshout, J. J., and Wieling, W. (1992). Treatment of orthostatic hypotension with sleeping in the head-up tilt position, alone and in combination with fludrocortisone. J. Intern. Med. 232, 139-145. doi:10.1111/j.1365-2796.1992.tb00563.x
135. Ten Harkel, A. D., van Lieshout, J. J., and Wieling, W. (1994). Effects of leg muscle pumping and tensing on orthostatic arterial pressure: a study in normal subjects and patients with autonomic failure. Clin. Sci. 87, 553-558.
136. Thomaides, T., Bleasdale-Barr, K., Chaudhuri, K. R., Pavitt, D., Marsden, C. D., and Mathias, C. J. (1993). Cardiovascular and hormonal responses to liquid food challenge in idiopathic Parkinson's disease, multiple system atrophy, and pure autonomic failure. Neurology 43, 900-904. doi:10.1212/WNL.43.5.900
137. Tolcapone Study Group. (1999). Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Tolcapone Study Group. Mov. Disord. 14, 38-44.
138. Tolosa, E., and Stern, M. B. (2012). Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease. Eur. J. Neurol. 19, 258-264. doi:10.1111/j.1468-1331.2011.03484.x
139. Turkka, J., Suominen, K., Tolonen, U., Sotaniemi, K., and Myllyla, V. V. (1997). Selegiline diminishes cardiovascular autonomic responses in Parkinson's disease. Neurology 48, 662-667. doi:10.1212/WNL.48.3.662
140. Turnbull, K., Caslake, R., Macleod, A., Ives, N., Stowe, R., Counsell, C. (2005). Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane Database Syst. Rev. 2005:CD004898. doi:10.1002/14651858.CD004898.pub2
141. Tutaj, M., Marthol, H., Berlin, D., Brown, C. M., Axelrod, F. B., and Hilz, M. J. (2006). Effect of physical countermaneuvers on orthostatic hypotension in familial dysautonomia. J. Neurol. 253, 65-72. doi:10.1007/s00415-005-0928-3
142. Tyne, H. L., Parsons, J., Sinnott, A., Fox, S. H., Fletcher, N. A., and Steiger, M. J. (2004). A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease. J. Neurol. 251, 1370-1374. doi:10.1007/s00415-004-0547-4
143. UCB, Inc. (2003). "An open-label extension trial to assess the safety of long-term treatment of rotigotine in advanced-stage Parkinson's disease," in ClinicalTrials.gov (Bethesda, MD: US National Library of Medicine). Available at: http://www.clinicaltrials.gov/ct2/show/results/NCT00501969 [accessed February 22, 2013].
144. van Lieshout, J. J., ten Harkel, A. D., and Wieling, W. (2000). Fludrocortisone and sleeping in the head-up position limit the postural decrease in cardiac output in autonomic failure. Clin. Auton. Res. 10, 35-42. doi:10.1007/BF02291388
145. Velseboer, D. C., de Haan, R. J., Wieling, W., Goldstein, D. S., and de Bie, R. M. (2011). Prevalence of orthostatic hypotension in Parkinson's disease: a systematic review and meta-analysis. Parkinsonism Relat. Disord. 17, 724-729. doi:10.1016/j.parkreldis.2011.04.016
146. Waters, W. W., Platts, S. H., Mitchell, B. M., Whitson, P. A., and Meck, J. V. (2005). Plasma volume restoration with salt tablets and water after bed rest prevents orthostatic hypotension and changes in supine hemodynamic and endocrine variables. Am. J. Physiol. Heart Circ. Physiol. 288, H839-H847. doi:10.1152/ajpheart.00220.2004
147. Wieling, W., Van Lieshout, J. J., and Hainsworth, R. (2002). Extracellular fluid volume expansion in patients with posturally related syncope. Clin. Auton. Res. 12, 242-249. doi:10.1007/s10286-002-0024-z
148. Wieling, W., van Lieshout, J. J., and van Leeuwen, A. M. (1993). Physical manoeuvres that reduce postural hypotension in autonomic failure. Clin. Auton. Res. 3, 57-65. doi:10.1007/BF01819146
149. Zesiewicz, T. A., Sullivan, K. L., Arnulf, I., Chaudhuri, K. R., Morgan, J. C., Gronseth, G. S., et al. (2010). Practice parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 74, 924-931. doi:10.1212/WNL.0b013e3181d55f24